| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th December 2020 | Randal J Kirk | 1,704 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 70,092 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 18,482 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 18,482 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 199,682 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 303 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 30 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 1,848 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 303 | Other acquisition or disposition | $0.00 | |
| 17th December 2020 | Randal J Kirk | 3,637 | Other acquisition or disposition | $0.00 |
Histogenics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
Ticker: HSGX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1372299
Employees: 49
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $700 Th for the period Apr 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $200 Th for the period Apr 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $500 Th for the period Apr 2020 to Jun 2020 in the context of Research and development expense
Restructuring Charges of $700 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $200 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $500 Th for the period Jan 2020 to Jun 2020 in the context of Research and development expense
Restructuring Charges of $694 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Fundamentals
Cash at Carrying Value: $15 M (0%)
Assets, Current: $23 M (45%)
Property, Plant and Equipment, Net: $232 Th (4%)
Other Assets, Noncurrent: $483 Th (-27%)
Assets: $24 M (41%)
Accounts Payable, Current: $508 Th (-73%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $7 M (54%)
Long-term Debt, Excluding Current Maturities: $2 M (88%)
Other Liabilities, Noncurrent: $0 (-100%)
Liabilities: $9 M (57%)
Common Stock, Value, Issued: $1 M (156%)
Common Stock, Shares, Issued: $135 M (156%)
Retained Earnings (Accumulated Deficit): $59 M (0%)
Treasury Stock, Value: $479 Th (0%)
Stockholders' Equity (Parent): $15 M (0%)
Liabilities and Equity: $24 M (41%)
General and Administrative Expenses: $2 M (-56%)
Operating Income/Loss: $3 M (-53%)
Other Income, net: $248 Th (-5%)
